SCHEMBL223031

SCHEMBL223031

O=C(O[C@@](C(=O)O)(C(=O)c1ccccc1)[C@H](O)C(=O)O)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.43
TP53 P04637 1/20 0.43
LMNA P02545 2/20 0.41
F2 P00734 1/20 0.41
ALDH1A1 P00352 4/20 0.41
CES1 P23141 2/20 0.39
MAPK1 P28482 1/20 0.39
HIF1A Q16665 1/20 0.39
TDP1 Q9NUW8 5/20 0.38
HSD17B10 Q99714 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
SRC P12931 1/20 0.37
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36
ADRB3 P13945 1/20 0.36
KMT2A Q03164 3/20 0.35
MAPT P10636 3/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL221679 1.00 TSHR (0.43) TSHRTP53LMNAF2ALDH1A1
SCHEMBL27362899 1.00 TSHR (0.43) TSHRTP53LMNAF2ALDH1A1
SCHEMBL7686 1.00 TSHR (0.43) TSHRTP53LMNAF2ALDH1A1
SCHEMBL2904556 1.00 TSHR (0.43) TSHRTP53LMNAF2ALDH1A1
SCHEMBL1483657 1.00 TSHR (0.43) TSHRTP53LMNAF2ALDH1A1
SCHEMBL3946464 0.98 TSHR (0.42) TSHRTP53LMNAF2ALDH1A1
Water SCHEMBL1818831 0.98 TSHR (0.42) TSHRTP53LMNAF2ALDH1A1
Water SCHEMBL789812 0.98 TSHR (0.42) TSHRTP53LMNAF2ALDH1A1
Ammonia Solution, Strong SCHEMBL11444698 0.98 TSHR (0.42) TSHRTP53LMNAF2ALDH1A1
SCHEMBL11542849 0.98 TSHR (0.42) TSHRTP53LMNAF2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1773 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132108-A1 PREPARATION OF MESEMBRINE KANNA HEALTH LTD (GB) 2026-05-14 US claimed
US-20260125390-A1 SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME KURA ONCOLOGY INC (US) 2026-05-07 US claimed
EP-4720073-A1 SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS Kura Oncology, Inc. (US) 2026-04-08 EP claimed
EP-4598904-A1 PREPARATION OF MESEMBRINE Kanna Health Limited (GB) 2025-08-13 EP claimed
US-20250215005-A1 PROCESS FOR PREPARATION OF RUXOLITINIB ALIVUS LIFE SCIENCES LIMITED (IN) 2025-07-03 US claimed
WO-2025133917-A1 PROCESS FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5- ETHOXY-1, 4-DIHYDRO-2,8-DIMETHYL-1,6-NAPTHYRIDINE-3-CARBOXAMIDE INDUSTRIALE CHIMICA S.R.L. (IT) 2025-06-26 WO claimed
US-20250115601-A1 PROCESS FOR THE PREPARATION OF FINERENONE AND INTERMEDIATES THEREOF ALIVUS LIFE SCIENCES LIMITED (IN) 2025-04-10 US claimed
EP-4525877-A1 PROCESS FOR PREPARATION OF RUXOLITINIB Alivus Life Sciences Limited (IN) 2025-03-26 EP claimed
EP-4526302-A1 PROCESS FOR THE PREPARATION OF FINERENONE AND INTERMEDIATES THEREOF Alivus Life Sciences Limited (IN) 2025-03-26 EP claimed
US-12247030-B2 Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine INCYTE HOLDINGS CORPORATION (US) 2025-03-11 US claimed
EP-0438796-A2 Process for the enantioselection synthesis of alkylated oxindoles used as intermediates in the preparation of physostigmine HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1991-07-31 EP claimed
WO-1991004253-A1 PREPARATION OF S-(-)- AND R-(+)-N-(QUINUCLIDINYL-3)-AMIDE CHIRON LABORATORIES A.S (NO) 1991-04-04 WO claimed
EP-0420120-A2 Optically active benzyl alcohol compound and pharmaceutical composition HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1991-04-03 EP claimed
EP-0418770-A2 Process for the chemical resolution of 5-alkoxy-substituted (+/-)-1,3-dimethyloxindolylethylamines HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1991-03-27 EP claimed
EP-0107825-B1 1,3,4,6,7,11B-HEXAHYDRO-7-ARYL-2H-PYRAZINO (2,1-ALPHA) ISOQUINOLINES USEFUL AS INTERMEDIATES AND PHARMACEUTICAL COMPOUNDS AND METHODS OF PREPARATION PENNWALT CORPORATION (US) 1988-03-02 EP claimed
EP-0092787-B1 PROCESS FOR THE PREPARATION OF A PHENYLALKYLAMINOETHYLSALICYLAMIDE SCHERING CORPORATION (US) 1986-08-27 EP claimed
EP-0107825-A1 1,3,4,6,7,11b-Hexahydro-7-aryl-2H-pyrazino (2,1-alpha) isoquinolines useful as intermediates and pharmaceutical compounds and methods of preparation PENNWALT CORPORATION (US) 1984-05-09 EP claimed
EP-0092787-A1 Process for the preparation of a phenylalkylaminoethylsalicylamide SCHERING CORPORATION (US) 1983-11-02 EP claimed
US-4370500-A Compound: d-N-(2-amino-2-phenethyl)-2-methoxyethylamine and process for preparing the same by selective crystallization AMERICAN CYANAMID COMPANY (US) 1983-01-25 US claimed
EP-0010851-A2 Process for the preparation of tetramisole AMERICAN CYANAMID COMPANY (US) 1980-05-14 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125390-A1 SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME FDPS, PCTP, MTTP TSHR 595/4885TP53 116/4885LMNA 3952/4885
US-12247030-B2 Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine DPYD, TYMS, TYMP TSHR 4626/4885TP53 1234/4885LMNA 2873/4885
US-20260132108-A1 PREPARATION OF MESEMBRINE BHMT, TMSB10, MSMO1 TSHR 4332/4885TP53 4739/4885LMNA 768/4885
US-20250215005-A1 PROCESS FOR PREPARATION OF RUXOLITINIB JAK2, JAK3, JAK1 TSHR 1759/4885TP53 1538/4885LMNA 4371/4885
US-20250115601-A1 PROCESS FOR THE PREPARATION OF FINERENONE AND INTERMEDIATES THEREOF CYP17A1, HSD17B7, CYP11B1 TSHR 2799/4885TP53 4116/4885LMNA 681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.